{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:47:08Z","timestamp":1793260028497,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.steroids.2019.108494","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T19:29:16Z","timestamp":1568143756000},"page":"108494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Nox1 downregulators: A new class of therapeutics"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-4341","authenticated-orcid":false,"given":"Matthias","family":"Barton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias R.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-8302","authenticated-orcid":false,"given":"Eric R.","family":"Prossnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10184","key":"10.1016\/j.steroids.2019.108494_b0005","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/S0140-6736(19)30041-8","article-title":"Health effects of dietary risks in 195 countries, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"393","author":"GBD Diet Collaborators","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.steroids.2019.108494_b0010","doi-asserted-by":"crossref","first-page":"e1288","DOI":"10.1016\/S2214-109X(18)30411-X","article-title":"Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target","volume":"6","author":"Cao","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"12","key":"10.1016\/j.steroids.2019.108494_b0015","doi-asserted-by":"crossref","first-page":"e1254","DOI":"10.1016\/S2214-109X(18)30473-X","article-title":"Progress towards reducing premature NCD mortality","volume":"6","author":"Adair","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"13","key":"10.1016\/j.steroids.2019.108494_b0020","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMsr1707974","article-title":"Investing in global health for our future","volume":"377","author":"Dzau","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.steroids.2019.108494_b0025","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.jacc.2017.11.009","article-title":"The future of the United States: a report of the national academies of sciences, medicine, the future role of the United States in global health: emphasis on cardiovascular disease","volume":"70","author":"Fuster","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl. 2","key":"10.1016\/j.steroids.2019.108494_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000066416","article-title":"The global epidemic of atherosclerotic cardiovascular disease","volume":"11","author":"Yusuf","year":"2002","journal-title":"Med. Princ. Pract."},{"issue":"5","key":"10.1016\/j.steroids.2019.108494_b0035","article-title":"Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy","volume":"32","author":"Barton","year":"2016","journal-title":"Can. J. Cardiol."},{"issue":"5","key":"10.1016\/j.steroids.2019.108494_b0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.freeradbiomed.2010.04.030","article-title":"NADPH oxidases in cardiovascular disease","volume":"49","author":"Brandes","year":"2010","journal-title":"Free Radic. Biol. Med."},{"issue":"13","key":"10.1016\/j.steroids.2019.108494_b0045","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","article-title":"Endothelial nitric oxide synthase in vascular disease: from marvel to menace","volume":"113","author":"F\u00f6rstermann","year":"2006","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.steroids.2019.108494_b0050","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.2174\/1389201011208062456","article-title":"Novel therapeutic approaches in limiting oxidative stress and inflammation","volume":"13","author":"Spychalowicz","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"5\u20136","key":"10.1016\/j.steroids.2019.108494_b0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.vph.2012.02.012","article-title":"Targeting NADPH oxidases in vascular pharmacology","volume":"56","author":"Schramm","year":"2012","journal-title":"Vasc.Pharmacol."},{"issue":"9374","key":"10.1016\/j.steroids.2019.108494_b0060","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0140-6736(03)13637-9","article-title":"Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials","volume":"361","author":"Vivekananthan","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/ajcn\/84.4.880","article-title":"Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials","volume":"84","author":"Bleys","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0070","first-page":"288","article-title":"Molecular mechanisms of hypertension\u2013reactive oxygen species and antioxidants: a basic science update for the clinician","volume":"28","author":"Montezano","year":"2012","journal-title":"Can. J. Cardiol."},{"issue":"10","key":"10.1016\/j.steroids.2019.108494_b0075","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/CIRCRESAHA.111.243972","article-title":"Biochemistry physiology, and pathophysiology of NADPH oxidases in the cardiovascular system","volume":"110","author":"Lassegue","year":"2012","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.steroids.2019.108494_b0080","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1172\/JCI200314172","article-title":"Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension","volume":"111","author":"Landmesser","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3400\/avd.ra.17-00134","article-title":"Nitric oxide: from good to bad","volume":"11","author":"Vanhoutte","year":"2018","journal-title":"Ann. Vasc. Dis."},{"issue":"8","key":"10.1016\/j.steroids.2019.108494_b0090","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1074\/jbc.M209813200","article-title":"Down-regulation of rac-1 GTPase by estrogen","volume":"278","author":"Laufs","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/ATVBAHA.118.312105","article-title":"Primum non nocere: why calcitriol (\u201cvitamin\u201d D) hormone therapy is not a magic bullet","volume":"39","author":"Barton","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.steroids.2019.108494_b0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jsbmb.2017.03.019","article-title":"GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases","volume":"176","author":"Meyer","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"10.1016\/j.steroids.2019.108494_b0105","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1089\/ars.2013.5814","article-title":"Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement","volume":"23","author":"Altenh\u00f6fer","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.steroids.2019.108494_b0110","first-page":"17","article-title":"Mammalian NADPH oxidases","volume":"2019","author":"Buvelot","year":"1982","journal-title":"Methods Mol. Biol."},{"issue":"17","key":"10.1016\/j.steroids.2019.108494_b0115","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1089\/ars.2013.5607","article-title":"NADPH oxidases in vascular pathology","volume":"20","author":"Konior","year":"2014","journal-title":"Antioxid. Redox Signal."},{"issue":"9","key":"10.1016\/j.steroids.2019.108494_b0120","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/CIRCRESAHA.112.267054","article-title":"Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase","volume":"110","author":"Schr\u00f6der","year":"2012","journal-title":"Circ. Res."},{"issue":"452","key":"10.1016\/j.steroids.2019.108494_b0125","doi-asserted-by":"crossref","first-page":"ra105","DOI":"10.1126\/scisignal.aag0240","article-title":"Obligatory role for GPER in cardiovascular aging and disease","volume":"9","author":"Meyer","year":"2016","journal-title":"Sci Signal"},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.stem.2013.04.001","article-title":"ROS are required for mouse spermatogonial stem cell self-renewal","volume":"12","author":"Morimoto","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0135","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900374","article-title":"ROS amplification drives mouse spermatogonial stem cell self-renewal","volume":"2","author":"Morimoto","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.steroids.2019.108494_b0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2019.01.028","article-title":"ROS-generating oxidase NOX1 promotes the self-renewal activity of CD133+ thyroid cancer cells through activation of the Akt signaling","volume":"447","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jash.2011.02.001","article-title":"Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR","volume":"5","author":"Briones","year":"2011","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/HJH.0000000000000801","article-title":"Hu antigen R is required for NOX-1 but not NOX-4 regulation by inflammatory stimuli in vascular smooth muscle cells","volume":"34","author":"Aguado","year":"2016","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nchembio775","article-title":"Virtual and biomolecular screening converge on a selective agonist for GPR30","volume":"2","author":"Bologa","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.118.036854","article-title":"HuR-ry up: how hydrogen sulfide protects against atherosclerosis","volume":"139","author":"Barton","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.steroids.2019.108494_b0165","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/hh0901.090299","article-title":"Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways","volume":"88","author":"Lassegue","year":"2001","journal-title":"Circ. Res."},{"issue":"1\u20132","key":"10.1016\/j.steroids.2019.108494_b0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0378-1119(01)00449-8","article-title":"Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5","volume":"269","author":"Cheng","year":"2001","journal-title":"Gene"},{"issue":"48","key":"10.1016\/j.steroids.2019.108494_b0175","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1093\/eurheartj\/ehv460","article-title":"The NADPH oxidase Nox4 has anti-atherosclerotic functions","volume":"36","author":"Sch\u00fcrmann","year":"2015","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0180","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/ATVBAHA.111.226894","article-title":"No superoxide\u2013no stress?: Nox4, the good NADPH oxidase!","volume":"31","author":"Brandes","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/ndt\/gfy161","article-title":"Potential benefits and harms of NADPH oxidase type 4 in the kidneys and cardiovascular system","volume":"34","author":"Rajaram","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0190","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/ATVBAHA.110.219238","article-title":"Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo","volume":"31","author":"Ray","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.steroids.2019.108494_b0195","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41044","article-title":"Myocardial NADPH oxidase-4 regulates the physiological response to acute exercise","volume":"7","author":"Hancock","year":"2018","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.steroids.2019.108494_b0200","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1113\/EP086204","article-title":"NOX5: molecular biology and pathophysiology","volume":"104","author":"Touyz","year":"2019","journal-title":"Exp. Physiol."},{"issue":"10","key":"10.1016\/j.steroids.2019.108494_b0205","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2337\/db16-1585","article-title":"NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy","volume":"66","author":"Jha","year":"2017","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.steroids.2019.108494_b0210","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s00125-019-4924-z","article-title":"Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse","volume":"62","author":"Jha","year":"2019","journal-title":"Diabetologia"},{"issue":"11\u201312","key":"10.1016\/j.steroids.2019.108494_b0215","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.drudis.2006.04.003","article-title":"Vascular NADPH oxidases as drug targets for novel antioxidant strategies","volume":"11","author":"Guzik","year":"2006","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.steroids.2019.108494_b0220","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/01.RES.0000014434.48463.35","article-title":"Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179","volume":"90","author":"Kramer","year":"2002","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0225","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0022-3565(24)36715-1","article-title":"Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries","volume":"281","author":"Li","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5 Suppl. 1","key":"10.1016\/j.steroids.2019.108494_b0230","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1097\/00005344-200036051-00072","article-title":"Endothelin regulates angiotensin-converting enzyme in the mouse kidney","volume":"36","author":"Barton","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1 Pt 2","key":"10.1016\/j.steroids.2019.108494_b0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.HYP.35.1.329","article-title":"Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin","volume":"35","author":"Barton","year":"2000","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.steroids.2019.108494_b0240","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/acs.jmedchem.5b00760","article-title":"Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer","volume":"58","author":"McDonnell","year":"2015","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.steroids.2019.108494_b0245","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrendo.2011.122","article-title":"The G-protein-coupled estrogen receptor GPER in health and disease","volume":"7","author":"Prossnitz","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0250","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1021\/jm00004a014","article-title":"Dual-acting thromboxane receptor antagonist\/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids","volume":"38","author":"Faull","year":"1995","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.steroids.2019.108494_b0255","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1021\/jm00010a005","article-title":"A novel approach to dual-acting thromboxane receptor antagonist\/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors","volume":"38","author":"Ackerley","year":"1995","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.steroids.2019.108494_b0260","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acschemneuro.8b00618","article-title":"Dual 5-HT6 and D3 receptor antagonists in a group of 1 H-pyrrolo[3,2- c]quinolines with neuroprotective and procognitive activity","volume":"10","author":"Grychowska","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.steroids.2019.108494_b0265","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/17469899.2013.840095","article-title":"Emergence of dual VEGF and PDGF antagonists in the treatment of exudative age-related macular degeneration","volume":"8","author":"Kudelka","year":"2013","journal-title":"Expert. Rev. Ophthalmol."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0270","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.103.055855","article-title":"Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension","volume":"309","author":"Kowala","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.steroids.2019.108494_b0275","doi-asserted-by":"crossref","first-page":"30661","DOI":"10.1039\/C6RA00589F","article-title":"Exploration of 6,7-dimethoxyquinazoline derivatives as dual acting \u03b11- and AT1-receptor antagonists: synthesis, evaluation, pharmacophore & 3D-QSAR modeling and receptor docking studies","volume":"6","author":"Agrawal","year":"2016","journal-title":"RSC Adv."},{"issue":"12","key":"10.1016\/j.steroids.2019.108494_b0280","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/13543784.2013.833182","article-title":"New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and beta2 agonists in combination or combined into a single molecule","volume":"22","author":"Norman","year":"2013","journal-title":"Expert. Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0285","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.00165712","article-title":"A new class of bronchodilator improves lung function in COPD: a trial with GSK961081","volume":"42","author":"Wielders","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"22","key":"10.1016\/j.steroids.2019.108494_b0290","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1016\/j.bmc.2009.09.023","article-title":"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles","volume":"17","author":"Heffernan","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0295","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41467-019-10462-z","article-title":"XX sex chromosome complement promotes atherosclerosis in mice","volume":"10","author":"AlSiraj","year":"2019","journal-title":"Nat. Commun."},{"issue":"6748","key":"10.1016\/j.steroids.2019.108494_b0300","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/43459","article-title":"Cell transformation by the superoxide-generating oxidase Mox1","volume":"401","author":"Suh","year":"1999","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0305","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/CS20150404","article-title":"Nox1 in cardiovascular diseases: regulation and pathophysiology","volume":"130","author":"Gimenez","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"issue":"501","key":"10.1016\/j.steroids.2019.108494_b0310","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaj1784","article-title":"The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1","volume":"10","author":"Meijles","year":"2017","journal-title":"Sci Signal"},{"issue":"51","key":"10.1016\/j.steroids.2019.108494_b0315","doi-asserted-by":"crossref","first-page":"36437","DOI":"10.1074\/jbc.M113.521344","article-title":"Selective recapitulation of conserved and nonconserved regions of putative NOXA1 protein activation domain confers isoform-specific inhibition of Nox1 oxidase and attenuation of endothelial cell migration","volume":"288","author":"Ranayhossaini","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.steroids.2019.108494_b0320","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1073\/pnas.86.19.7321","article-title":"Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins","volume":"86","author":"Costa","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0325","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.tips.2005.12.007","article-title":"Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery","volume":"27","author":"Bond","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0330","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2017.07.009","article-title":"How ligands illuminate GPCR molecular pharmacology","volume":"170","author":"Wacker","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0335","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1210\/me.2014-1315","article-title":"Minireview: tipping the balance: ligand-independent activation of steroid receptors","volume":"29","author":"Bennesch","year":"2015","journal-title":"Mol. Endocrinol."},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0340","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.111.173427","article-title":"Estrogen-independent activation of estrogen receptors","volume":"57","author":"Barton","year":"2011","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0345","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/HYPERTENSIONAHA.110.167650","article-title":"Activation of estrogen receptor-alpha and of angiotensin-converting enzyme 2 suppresses ischemic brain damage in oophorectomized rats","volume":"57","author":"Shimada","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.steroids.2019.108494_b0350","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mce.2016.11.019","article-title":"Unliganded estrogen receptor alpha regulates vascular cell function and gene expression","volume":"442","author":"Lu","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2019.108494_b0355","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2017.03.021","article-title":"Twenty years of the G protein-coupled estrogen receptor GPER: historical and personal perspectives","volume":"176","author":"Barton","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"10","key":"10.1016\/j.steroids.2019.108494_b0360","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1210\/mend.14.10.0532","article-title":"Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF","volume":"14","author":"Filardo","year":"2000","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0365","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1210\/mend.16.1.0758","article-title":"Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis","volume":"16","author":"Filardo","year":"2002","journal-title":"Mol. Endocrinol."},{"issue":"5715","key":"10.1016\/j.steroids.2019.108494_b0370","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.1106943","article-title":"A transmembrane intracellular estrogen receptor mediates rapid cell signaling","volume":"307","author":"Revankar","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0375","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1210\/en.2004-1064","article-title":"Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells","volume":"146","author":"Thomas","year":"2005","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0380","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nchembio.168","article-title":"In vivo effects of a GPR30 antagonist","volume":"5","author":"Dennis","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.steroids.2019.108494_b0385","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jsbmb.2011.07.002","article-title":"Identification of a GPER\/GPR30 antagonist with improved estrogen receptor counterselectivity","volume":"127","author":"Dennis","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6312","key":"10.1016\/j.steroids.2019.108494_b0390","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.354.6312.593-a","article-title":"Keeping hearts and blood vessels young","volume":"354","author":"Wong","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.steroids.2019.108494_b0395","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lfs.2016.02.041","article-title":"GPER is required for the age-dependent upregulation of the myocardial endothelin system","volume":"159","author":"Meyer","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.steroids.2019.108494_b0400","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsbmb.2017.05.006","article-title":"Role of GPER in estrogen-dependent nitric oxide formation and vasodilation","volume":"176","author":"Fredette","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0405","doi-asserted-by":"crossref","first-page":"H1055","DOI":"10.1152\/ajpheart.00878.2009","article-title":"Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries","volume":"298","author":"Broughton","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.steroids.2019.108494_b0410","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1038\/srep07564","article-title":"G protein-coupled estrogen receptor protects from atherosclerosis","volume":"4","author":"Meyer","year":"2014","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.steroids.2019.108494_b0415","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2014.02.002","article-title":"Estrogen biology: new insights into GPER function and clinical opportunities","volume":"389","author":"Prossnitz","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2019.108494_b0420","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/472720","article-title":"G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth","volume":"2013","author":"Petrie","year":"2013","journal-title":"Obstet. Gynecol. Int."},{"issue":"9","key":"10.1016\/j.steroids.2019.108494_b0425","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1073\/pnas.89.9.4037","article-title":"Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover","volume":"89","author":"Dauvois","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0430","doi-asserted-by":"crossref","first-page":"H282","DOI":"10.1152\/ajpheart.00231.2012","article-title":"Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18","volume":"303","author":"Valente","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0435","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1038\/s41598-018-21899-5","article-title":"Reactive oxygen species mediate the suppression of arterial smooth muscle T-type Ca(2+) channels by angiotensin II","volume":"8","author":"Hashad","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.steroids.2019.108494_b0440","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/hh1701.096037","article-title":"Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice","volume":"89","author":"Rey","year":"2001","journal-title":"Circ. Res."},{"issue":"16","key":"10.1016\/j.steroids.2019.108494_b0445","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","article-title":"Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease","volume":"101","author":"Sch\u00e4chinger","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0450","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.febslet.2005.12.049","article-title":"Decreased blood pressure in NOX1-deficient mice","volume":"580","author":"Gavazzi","year":"2006","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0455","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/ATVBAHA.112.249516","article-title":"Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-\/- mice","volume":"32","author":"Aono","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.steroids.2019.108494_b0460","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.redox.2015.08.020","article-title":"Reperfusion injury and reactive oxygen species: the evolution of a concept","volume":"6","author":"Granger","year":"2015","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0465","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jacc.2017.05.035","article-title":"Impact of oxidative stress on the heart and vasculature: part 2 of a 3-part series","volume":"70","author":"M\u00fcnzel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7752","key":"10.1016\/j.steroids.2019.108494_b0470","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0475","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41598-018-37951-3","article-title":"GPER activation protects against epithelial barrier disruption by Staphylococcus aureus alpha-toxin","volume":"9","author":"Triplett","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.steroids.2019.108494_b0480","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1210\/en.2014-1890","article-title":"Measurement of a comprehensive sex steroid profile in rodent serum by high-sensitive gas chromatography-tandem mass spectrometry","volume":"156","author":"Nilsson","year":"2015","journal-title":"Endocrinology"},{"issue":"Suppl A","key":"10.1016\/j.steroids.2019.108494_b0485","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.genm.2008.03.004","article-title":"Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis","volume":"5","author":"Meyer","year":"2008","journal-title":"Gend Med"},{"key":"10.1016\/j.steroids.2019.108494_b0490","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/bs.apha.2016.05.003","article-title":"Estrogens and coronary artery disease: new clinical perspectives","volume":"77","author":"Meyer","year":"2016","journal-title":"Adv. Pharmacol."},{"issue":"11","key":"10.1016\/j.steroids.2019.108494_b0495","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/jgs.15141","article-title":"Evolution of a geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction","volume":"65","author":"Upadhya","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"issue":"7752","key":"10.1016\/j.steroids.2019.108494_b0500","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/d41586-019-00983-4","article-title":"A mouse model for the most common form of heart failure","volume":"568","author":"Amgalan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2019.108494_b0505","first-page":"404","article-title":"Western diet-fed, aortic-banded Ossabaw swine. A preclinical model of cardio-metabolic heart failure","volume":"4","author":"Olver","year":"2019","journal-title":"J. Am. Coll. Cardiol. Basic Trans. Sci."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0510","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/ars.2011.4176","article-title":"NADPH oxidase-derived H(2)O(2) contributes to angiotensin II-induced aldosterone synthesis in human and rat adrenal cortical cells","volume":"17","author":"Rajamohan","year":"2012","journal-title":"Antioxid. Redox Signal."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0515","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1006\/bbrc.1997.7394","article-title":"Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation","volume":"238","author":"Barton","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.steroids.2019.108494_b0520","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/01.HYP.0000149249.09147.b4","article-title":"Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition","volume":"44","author":"Ortmann","year":"2004","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.steroids.2019.108494_b0525","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneph0891","article-title":"Reversal of proteinuric renal disease and the emerging role of endothelin","volume":"4","author":"Barton","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"issue":"11","key":"10.1016\/j.steroids.2019.108494_b0530","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1097\/01.ASN.0000095248.91994.D3","article-title":"Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats","volume":"14","author":"Adamczak","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.steroids.2019.108494_b0535","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1681\/ASN.2014100971","article-title":"Regression of renal disease by angiotensin II antagonism Is caused by regeneration of kidney vasculature","volume":"27","author":"Remuzzi","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.steroids.2019.108494_b0540","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.freeradbiomed.2015.02.009","article-title":"NADPH oxidase NOX1 is involved in activation of protein kinase C and premature senescence in early stage diabetic kidney","volume":"83","author":"Zhu","year":"2015","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0545","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/labinvest.2017.2","article-title":"APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db\/db mice from renal injury","volume":"97","author":"Cha","year":"2017","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0550","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ckj\/sfs001","article-title":"Endothelin and the podocyte","volume":"5","author":"Barton","year":"2012","journal-title":"Clin Kidney J"},{"issue":"Suppl.","key":"10.1016\/j.steroids.2019.108494_b0555","first-page":"AP261","article-title":"GPER is required for age-dependent albuminuria and glomerulosclerosis: evidence for its role in podocyte injury and mesangial Nox1 regulation","volume":"72","author":"Meyer","year":"2018","journal-title":"Hypertension"},{"issue":"3\u20134","key":"10.1016\/j.steroids.2019.108494_b0560","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000478732","article-title":"GPER mediates functional endothelial aging in renal rteries","volume":"100","author":"Meyer","year":"2017","journal-title":"Pharmacology"},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0565","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.freeradbiomed.2012.05.007","article-title":"Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4\/NOX1 inhibitor in vivo","volume":"53","author":"Jiang","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.steroids.2019.108494_b0570","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.3892\/mmr.2016.5090","article-title":"Effects of NOX1 on fibroblastic changes of endothelial cells in radiationinduced pulmonary fibrosis","volume":"13","author":"Choi","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"11","key":"10.1016\/j.steroids.2019.108494_b0575","doi-asserted-by":"crossref","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","article-title":"Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes","volume":"308","author":"Gorin","year":"2015","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"Pt 3","key":"10.1016\/j.steroids.2019.108494_b0580","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/brain\/aws012","article-title":"NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury","volume":"135","author":"Fischer","year":"2012","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.steroids.2019.108494_b0585","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neulet.2010.10.032","article-title":"Anxiety-like behavior in the elevated-plus maze tests and enhanced IL-1beta, IL-6, NADPH oxidase-1, and iNOS mRNAs in the hippocampus during early stage of adjuvant arthritis in rats","volume":"487","author":"Skurlova","year":"2011","journal-title":"Neurosci. Lett."},{"issue":"6450","key":"10.1016\/j.steroids.2019.108494_b0590","doi-asserted-by":"crossref","first-page":"eaav9518","DOI":"10.1126\/science.aav9518","article-title":"Amyloid beta oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes","volume":"365","author":"Nortley","year":"2019","journal-title":"Science"},{"issue":"6450","key":"10.1016\/j.steroids.2019.108494_b0595","first-page":"eaav9518","article-title":"Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia","volume":"365","author":"Barton","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.steroids.2019.108494_b0600","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1172\/JCI125173","article-title":"Nox2 contributes to age-related oxidative damage to neurons and the cerebral vasculature","volume":"130","author":"Fan","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0605","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00125-014-3398-2","article-title":"Inhibition of NADPH oxidase-1 preserves beta cell function","volume":"58","author":"Weaver","year":"2015","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.steroids.2019.108494_b0610","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1476-5381.2012.02130.x","article-title":"The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner","volume":"168","author":"Vara","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"61","key":"10.1016\/j.steroids.2019.108494_b0615","doi-asserted-by":"crossref","first-page":"103710","DOI":"10.18632\/oncotarget.21780","article-title":"Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain \/ Nox1 pathway","volume":"8","author":"Chocry","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.steroids.2019.108494_b0620","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1038\/s41388-019-0702-0","article-title":"NF-kappaB-induced NOX1 activation promotes gastric tumorigenesis through the expansion of SOX2-positive epithelial cells","volume":"38","author":"Echizen","year":"2019","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.steroids.2019.108494_b0625","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/cb100219n","article-title":"A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells","volume":"5","author":"Gianni","year":"2010","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0630","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.11.019","article-title":"NADPH oxidase 1 in liver macrophages promotes inflammation and tumor development in mice","volume":"156","author":"Liang","year":"2019","journal-title":"Gastroenterology"},{"issue":"31","key":"10.1016\/j.steroids.2019.108494_b0635","doi-asserted-by":"crossref","first-page":"50596","DOI":"10.18632\/oncotarget.10585","article-title":"Cambogin exerts anti-proliferative and pro-apoptotic effects on breast adenocarcinoma through the induction of NADPH oxidase 1 and the alteration of mitochondrial morphology and dynamics","volume":"7","author":"Shen","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.steroids.2019.108494_b0640","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800265","article-title":"Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy","volume":"2","author":"Stalin","year":"2019","journal-title":"Life Sci. Alliance"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X19301849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X19301849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:07:12Z","timestamp":1758535632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X19301849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":128,"alternative-id":["S0039128X19301849"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2019.108494","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nox1 downregulators: A new class of therapeutics","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2019.108494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108494"}}